Meropenem versus tobramycin plus clindamycin for treatment of intraabdominal infections

Results of a prospective, randomized, double-blind clinical trial

Robert E. Condon, Alonzo P. Walker, Kenneth R. Sirinek, Patrick W. White, Timothy Fabian, Ronald L. Nichols, Samuel E. Wilson

Research output: Contribution to journalArticle

72 Citations (Scopus)

Abstract

The efficacy of meropenem was compared to that of the combination of tobramycin plus clindamycin (T/C) in a multiinstitutional clinical trial of treatment for patients suffering intraabdominal infection. Among the 177 patients enrolled and randomized, 127 were clinically evaluable and 86 were microbiologically evaluable. Analysis of data on an intent-to-treat basis for all randomized patientsand on the basis of a successful outcome (absence of any infection) for clinically evaluable patientsfailed to detect any difference in efficacy between the two treatments. Infection was cleared in 92% of meropenem- and 89% of T/C-treated clinically evaluable patients. Eradication of pathogens also wassimilar in the two treatment groups. Overall, adverse drug experiences were comparable between the two treatment groups, with the exception of an increase in serum creatinine level (which occurred more frequently in patients receiving T/C). Meropenem appears to be efficacious for the treatment of intraabdominal infections.

Original languageEnglish (US)
Pages (from-to)544-550
Number of pages7
JournalClinical Infectious Diseases
Volume21
Issue number3
DOIs
StatePublished - Jan 1 1995

Fingerprint

meropenem
Intraabdominal Infections
Tobramycin
Clindamycin
Clinical Trials
Therapeutics
Infection
Creatinine

All Science Journal Classification (ASJC) codes

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Meropenem versus tobramycin plus clindamycin for treatment of intraabdominal infections : Results of a prospective, randomized, double-blind clinical trial. / Condon, Robert E.; Walker, Alonzo P.; Sirinek, Kenneth R.; White, Patrick W.; Fabian, Timothy; Nichols, Ronald L.; Wilson, Samuel E.

In: Clinical Infectious Diseases, Vol. 21, No. 3, 01.01.1995, p. 544-550.

Research output: Contribution to journalArticle

Condon, Robert E. ; Walker, Alonzo P. ; Sirinek, Kenneth R. ; White, Patrick W. ; Fabian, Timothy ; Nichols, Ronald L. ; Wilson, Samuel E. / Meropenem versus tobramycin plus clindamycin for treatment of intraabdominal infections : Results of a prospective, randomized, double-blind clinical trial. In: Clinical Infectious Diseases. 1995 ; Vol. 21, No. 3. pp. 544-550.
@article{ea420801d3a74062baf12f2ffed42098,
title = "Meropenem versus tobramycin plus clindamycin for treatment of intraabdominal infections: Results of a prospective, randomized, double-blind clinical trial",
abstract = "The efficacy of meropenem was compared to that of the combination of tobramycin plus clindamycin (T/C) in a multiinstitutional clinical trial of treatment for patients suffering intraabdominal infection. Among the 177 patients enrolled and randomized, 127 were clinically evaluable and 86 were microbiologically evaluable. Analysis of data on an intent-to-treat basis for all randomized patientsand on the basis of a successful outcome (absence of any infection) for clinically evaluable patientsfailed to detect any difference in efficacy between the two treatments. Infection was cleared in 92{\%} of meropenem- and 89{\%} of T/C-treated clinically evaluable patients. Eradication of pathogens also wassimilar in the two treatment groups. Overall, adverse drug experiences were comparable between the two treatment groups, with the exception of an increase in serum creatinine level (which occurred more frequently in patients receiving T/C). Meropenem appears to be efficacious for the treatment of intraabdominal infections.",
author = "Condon, {Robert E.} and Walker, {Alonzo P.} and Sirinek, {Kenneth R.} and White, {Patrick W.} and Timothy Fabian and Nichols, {Ronald L.} and Wilson, {Samuel E.}",
year = "1995",
month = "1",
day = "1",
doi = "10.1093/clinids/21.3.544",
language = "English (US)",
volume = "21",
pages = "544--550",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Meropenem versus tobramycin plus clindamycin for treatment of intraabdominal infections

T2 - Results of a prospective, randomized, double-blind clinical trial

AU - Condon, Robert E.

AU - Walker, Alonzo P.

AU - Sirinek, Kenneth R.

AU - White, Patrick W.

AU - Fabian, Timothy

AU - Nichols, Ronald L.

AU - Wilson, Samuel E.

PY - 1995/1/1

Y1 - 1995/1/1

N2 - The efficacy of meropenem was compared to that of the combination of tobramycin plus clindamycin (T/C) in a multiinstitutional clinical trial of treatment for patients suffering intraabdominal infection. Among the 177 patients enrolled and randomized, 127 were clinically evaluable and 86 were microbiologically evaluable. Analysis of data on an intent-to-treat basis for all randomized patientsand on the basis of a successful outcome (absence of any infection) for clinically evaluable patientsfailed to detect any difference in efficacy between the two treatments. Infection was cleared in 92% of meropenem- and 89% of T/C-treated clinically evaluable patients. Eradication of pathogens also wassimilar in the two treatment groups. Overall, adverse drug experiences were comparable between the two treatment groups, with the exception of an increase in serum creatinine level (which occurred more frequently in patients receiving T/C). Meropenem appears to be efficacious for the treatment of intraabdominal infections.

AB - The efficacy of meropenem was compared to that of the combination of tobramycin plus clindamycin (T/C) in a multiinstitutional clinical trial of treatment for patients suffering intraabdominal infection. Among the 177 patients enrolled and randomized, 127 were clinically evaluable and 86 were microbiologically evaluable. Analysis of data on an intent-to-treat basis for all randomized patientsand on the basis of a successful outcome (absence of any infection) for clinically evaluable patientsfailed to detect any difference in efficacy between the two treatments. Infection was cleared in 92% of meropenem- and 89% of T/C-treated clinically evaluable patients. Eradication of pathogens also wassimilar in the two treatment groups. Overall, adverse drug experiences were comparable between the two treatment groups, with the exception of an increase in serum creatinine level (which occurred more frequently in patients receiving T/C). Meropenem appears to be efficacious for the treatment of intraabdominal infections.

UR - http://www.scopus.com/inward/record.url?scp=0029156103&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029156103&partnerID=8YFLogxK

U2 - 10.1093/clinids/21.3.544

DO - 10.1093/clinids/21.3.544

M3 - Article

VL - 21

SP - 544

EP - 550

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 3

ER -